Gastric toxicity of antiplatelet therapy with low-dose aspirin

Drugs

Volumn 53, Issue 1, 1997, Pages 1-5

  Guslandi, Mario ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; SUCRALFATE;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DUODENUM MUCOSA; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; META ANALYSIS; ORAL DRUG ADMINISTRATION; SHORT SURVEY; STOMACH MUCOSA; STOMACH ULCER;

EID: 0031037170     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199753010-00001     Document Type: Short Survey

References (40)

1. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988; 296: 320-31
2. Manson JE, Stampfer MJ, Colditz GA, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 1991; 266: 521-7
3. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-94
4. Kurata JH, Abbey DE. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalization. J Clin Gastroenterol 1990; 12: 260-6
5. Laporte JR, Carne X, Vidal X, et al. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Lancet 1991; 337: 85-9
6. Levy M, Miller DR, Kaufman DW, et al. Major upper gastrointestinal tract bleeding: relation to use of aspirin and other nonnarcotic analgesics. Arch Intern Med 1988; 148: 281-5
7. Steering Committee of Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129-35
8. Slattery J, Warlow CP, Shorrock CM, et al. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin - analysis of gastrointestinal bleeding during the UK-TIA trial. Gut 1995; 37: 509-11
9. Weil J, Colin-Jones D, Langman MJS, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 827-30
10. Kaufman DW, Kelly JP, Sheehan JE, et al. Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding. Clin Pharmacol Ther 1993; 53: 485-94
11. Silagy CA, Mc Neil JJ, Donnan GA, et al. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther 1993; 54: 84-9
12. Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30mg vs 283mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261-6
13. Stalnikowicz-Darvasi R. Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis. J Clin Gastroenterol 1995; 21: 13-6
14. Lee M, Cruer B, Feldman M. Dose effects of aspirin and gastric prostaglandins and stomach mucosal injury. Ann Intern Med 1994; 120: 184-9
15. Guslandi M. NSAID gastropathy. In: Guslandi M, Braga PC, editors. Drug-induced injury to the digestive system. Heidelberg, Berlin: Springer-Verlag, 1993: 19-31
16. Zandomeneghi R, Serra L, Pavesi C, et al. Effects of aspirin and indomethacin on epidermal growth factor secretion in duodenal tissue fragments cultivated in vitro. Digestion 1992; 51: 37-41
17. Lee M, Aldred K, Lee E, Feldman M. Aspirin-induced acute gastric mucosal injury is a neutrophil-independent process in rats. Am J Physiol 1992; 263: G920-6
18. Pihan G, Regillo C, Szabo S. Free radicals and lipid peroxidation in ethanol- and aspirin-induced gastric mucosal injury. Dig Dis Sci 1987; 32: 1395-401
19. Graham DY, Lacey Smith J, Spjut HJ, et al. Gastric adaptation: studies in humans during continuous aspirin administration. Gastroenterology 1988; 95: 327-33
20. Konturek JW, Dembinski A, Stoll R, et al. Mucosal adaptation to aspirin-induced gastric damage in humans: studies on blood flow, gastric mucosal growth and neutrophil activation. Gut 1994; 35: 1197-204
21. Savon JJ, Allen ML, Di Marino AJ, et al. Gastrointestinal blood loss with low dose (325mg) plain and enteric-coated aspirin administration. Am J Gastroenterol 1995; 90: 581-5
22. Petroski D. Gastrointestinal blood loss with low-dose aspirin. Am J Gastroenterol 1995; 90: 2071
23. Caruso I, Bianchi Porro G. Gastroscopic evaluation of anti-inflammatory agents. BMJ 1980; 280: 75-8
24. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs: a randomised, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241-9
25. Simon B, Dammann HG, Muller P. Stomach tolerance of buffered and unbuffered low-dose acetylsalicylic acid: an endoscopic controlled double-blind study in volunteers. Z Gastroenterol 1990; 28: 137-8
26. Petroski D. Endoscopic comparison of three aspirin preparations and placebo. Clin Ther 1993; 15: 314-20
27. Hoftiezer JW, Burks M, Silvoso GR, et al. Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man. Lancet 1980; 1: 609-12
28. Petroski D. A comparison of enteric-coated aspirin granules with plain and buffered aspirin: a report of two studies. Am J Gastroenterol 1986; 81: 26-8
29. Jaszewski R. Frequency of gastroduodenal lesions in asymptomatic patients on chronic aspirin or nonsteroidal anti-inflammatory drug therapy. J Clin Gastroemerol 1990; 12: 10-2
30. Savon JJ, Allen ML, Di Marino AJ, et al. Gastrointestinal blood loss with low dose (350mg) plain and enteric-coated aspirin administration. Am J Gastroemerol 1995; 90: 581-5
31. French PC, Darekar BS, Mills JG, et al. Ranitidine in the prevention of non-steroidal anti-inflammatory drug-associated gastric and duodenal ulceration in arthritic patients. Eur J Gastroemerol Hepatol 1994; 6: 1141-7
32. Lanza F, Peace K, Gustitus L, et al. A blinded endoscopic comparative study of misoprostol versus sucralfate and placebo in the prevention of aspirin-induced gastric and duodenal ulceration. Am J Gastroenterol 1988; 83: 143-6
33. Agrawal NW, Roth S, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-nflammatory drug-induced gastric ulcer: a randomized, controlled trial. Ann Intern Med 1991; 115: 195-200
34. Silverstein FE, Kimmey MB, Saunders DR, et al. Gastric protection by misoprostol against 1300 mg of aspirin: an endoscopic study. Dig Dis Sci 1986; 31: 127S-41S
35. Jiranek GC, Kimmey BM, Saunders DR, et al. Misoprostol reduces gastroduodenal injury from one week of aspirin: an endoscopic study. Gastroenterology 1989; 96: 656-61
36. Raskin JB, White RH, Jaszewski R, et al. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind multicenter study. Am J Gastroenterol 1996; 91: 223-7
37. Valentini M, Cannizzaro R, Poletti M, et al. Non-steroidal anti-inflammatory drugs for cancer pain: comparison between misoprostol and ranitidine in prevention of upper gastrointestinal damage. J Clin Oncol 1995; 13: 2637-42
38. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995; 123: 344-50
39. Goddard AF, Donnelly MT, Filipowicz B, et al. Low-dose misoprostol as prophylaxis against low-dose aspirin-induced gastroduodenal mucosal injury [abstract]. Gut 1996; 39 Suppl. 1: A33
40. Bardhan KD, Bjarnason I, Scott DL, et al. The prevention and healing of acute non-steroidal anti-inflammatory drug-associated gastroduodenal mucosal damage by misoprostol. Br J Rheumatol 1993; 32: 990-5